



xing
cancer
care

Available Assays

TEST	GENES ANALYSED	DESCRIPTION	COST	
			TUMOUR SAMPLE	PAIRED NORMAL SAMPLE
Homologous Recombination Deficiency (HRD)	27 genes	Multi-gene test that analyses the entire coding regions of 27 key genes involved in homologous recombination repair deficiency. Aimed at breast, ovarian, prostate, and pancreatic cancers.	AUD1,000	(included)
	<i>BRCA1</i> methylation	Additional add-on to HRD	AUD500	
Solid Tumour Panel (STP)	47 genes involved in solid tumours	Multi-gene test that analyses hotspot alterations considered to be driving mutations in solid tumours; includes hotspots in 47 genes involved in colorectal, thyroid, melanoma, NSCLC, pancreatic, GIST, and glioma.	AUD1,000	N/A
XGP72	72 genes that are known to be involved in cancer (subset of XGP1000)	Multi-gene test for cancer predisposition and targeted treatment. Analyses coding regions of 72 of the most clinically relevant genes that are commonly associated with cancer or with an increased risk for cancer.	AUD1,000	(included) Unpaired normal sample AUD350
XGP1000	> 1,000 genes known to be involved in cancer	Multi-gene test that analyses coding regions of over 1,000 known cancer genes in order to identify clinically actionable genetic alterations that may be missed by smaller gene panel tests. Reports Tumour Mutation Burden (TMB). Only available for patients who have failed first line therapy.	TBD	(included)

Turn Around Times

TEST	TURN AROUND TIME
Homologous Recombination Deficiency (HRD)	2 weeks
Solid Tumour Panel (STP)	2 weeks
XGP72	2 - 4 weeks
XGP1000	2 - 4 weeks

Please see reverse for full gene list.

